Scott Gottlieb, MD, commissioner of the Food and Drug Administration, is resigning from his position, effective April 5th.
 
Dr. Gottlieb became commissioner in May 2017, and during his tenure, worked to foster competition and reduce the cost and availability of both brand and generic medicines. In his first year as commissioner, a record number of new and generic drugs were approved.

Dr. Gottlieb served as FDA Deputy Commissioner for Medical and Scientific Affairs from 2005-2007, and as a senior advisor to the FDA Commissioner from 2003-2004. He also served as the FDA’s Director of Medical Policy Development. Prior to his appointment, he served on the board of several pharma/biopharma companies and was a Resident Fellow at the American Enterprise Institute.
 
Dr. Gottlieb spoke at Contract Pharma’s 2015 Contracting & Outsourcing Conference about the economic and technological forces driving the transformation of healthcare. He is noted authority on pathways to successful development of new medical products.